Axa’s GeneDx Holdings WGS Stock Holding History

Axa’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-88,269	Closed	-$8.15M	–	1016
2025 Q2	$8.15M	Buy	+88,269	New	+$6.93M	0.02%	448

Other funds holding WGS

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Axa's WGS Position: Q3 2025 in Review

Axa sold out of GeneDx Holdings (WGS) in Q3 2025, closing a stake of 88,269 shares — an estimated $8.15M sold.

Axa first reported a position in WGS in Q2 2025 and held it in 1 quarter. The position peaked at $8.15M in Q2 2025. 268 funds tracked by Wall St. Rank hold WGS as of Q3 2025.

Axa reported no remaining GeneDx Holdings position as of Q3 2025 after selling out during the quarter.
Axa sold 88,269 GeneDx Holdings shares in Q3 2025, an estimated $8.15M.
Axa first reported a position in GeneDx Holdings in Q2 2025 and held it in 1 quarter.
Axa's GeneDx Holdings position peaked at $8.15M in Q2 2025.
268 funds tracked by Wall St. Rank held GeneDx Holdings as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.